In my years working with hospital pharmacies across the country, including VA Medical Centers, I've come to appreciate that VAMC pharmacies operate in a different league when it comes to controlled substance accountability. Not because they have more resources, but because the regulatory environment they operate in demands a level of rigor that most community hospitals simply haven't been required to match.

That's starting to change. DEA enforcement has intensified. State pharmacy boards are increasing scrutiny. And the consequences of controlled substance diversion — for patients, for staff, and for institutions — are too serious to treat as a back-burner compliance issue.

Here's what VAMC pharmacies do differently, and what community hospitals can realistically adopt from their playbook.

VA Medical Centers are subject to oversight from multiple federal agencies simultaneously: the DEA, the VA Office of Inspector General, and the Veterans Health Administration's own Pharmacy Benefits Management Services. This layered oversight creates an accountability environment where documentation gaps are not tolerated and discrepancies are investigated, not explained away.

The result is a set of operational practices that are more rigorous than what most community hospitals maintain — not because VAMC pharmacies are inherently better run, but because the consequences of falling short are more immediate and more severe.

VAMC pharmacies maintain perpetual inventory records for all Schedule II–V controlled substances. Every transaction — dispensing, waste, return, transfer — is documented in real time and reconciled against the running balance.

This isn't a periodic count. It's a continuous record that allows any discrepancy to be identified within hours, not days or weeks.

Most community hospital pharmacies maintain perpetual inventory for Schedule II substances but are less rigorous about Schedule III–V. VAMC pharmacies treat all controlled substances with the same accountability standard, regardless of schedule.

The practical implication: when a discrepancy occurs in a VAMC pharmacy, the investigation can typically be narrowed to a specific time window and a specific set of transactions. In a pharmacy without perpetual inventory, the investigation starts from scratch.

Partial vial waste is one of the most common vectors for controlled substance diversion. A nurse wastes 4 mg of an 8 mg morphine vial. If the waste isn't witnessed and documented by a second qualified individual, there's no way to verify that 4 mg was actually wasted rather than diverted.

VAMC pharmacies enforce dual verification for every controlled substance waste event without exception. The policy is clear, the expectation is consistent, and deviations are treated as accountability failures rather than documentation oversights.

In community hospital settings, dual verification policies often exist on paper but are inconsistently enforced in practice — particularly during high-volume periods or overnight shifts when a second witness isn't immediately available. VAMC pharmacies have built workflows that make dual verification the path of least resistance, not an additional step that gets skipped when things are busy.

At the end of every shift, VAMC pharmacy staff reconcile controlled substance counts against the perpetual inventory record. Discrepancies are documented and escalated before the shift ends — not carried forward to the next count.

This practice has two important effects. First, it catches diversion patterns early, before they compound. Second, it creates a clear accountability boundary: the outgoing shift is responsible for the inventory they hand off, and discrepancies discovered after the fact can be traced to a specific shift and a specific set of personnel.

Community hospitals that conduct controlled substance reconciliation only at the end of the day — or less frequently — have a much wider window during which diversion can occur undetected.

DEA Form 222 for Schedule II returns, proper manifesting for Schedule III–V, biennial inventory requirements — VAMC pharmacies execute these requirements with standardized protocols that don't vary based on who's handling the documentation.

The documentation is treated as a clinical procedure: there's a defined process, a defined standard, and a defined consequence for deviation. Staff are trained on the protocol, not just told to follow the regulations.

In community hospital pharmacies, DEA documentation is often handled by whoever is available, with varying levels of training and varying interpretations of the requirements. The result is inconsistency that creates both compliance risk and operational inefficiency.

Perhaps the most significant difference between VAMC pharmacies and typical community hospital pharmacies is the posture toward diversion: proactive detection versus reactive investigation.

VAMC pharmacies use data analytics to identify patterns that may indicate diversion — unusual dispensing frequency for specific medications, discrepancies between dispensed and administered quantities, access patterns that don't align with patient care assignments. These patterns are reviewed regularly, not just when a specific incident triggers an investigation.

This proactive approach means that diversion, when it occurs, is typically identified earlier — before it becomes a large-scale problem and before the evidence trail goes cold.

Most community hospital pharmacies investigate diversion after it's been reported or discovered. VAMC pharmacies look for it continuously.

I want to be clear: I'm not suggesting that community hospitals need to replicate the full VAMC accountability infrastructure. The regulatory environment is different, the oversight structure is different, and the resources available are different.

But there are specific practices that any hospital pharmacy can adopt without significant investment:

Extend perpetual inventory to Schedule III–V. If you're already maintaining perpetual inventory for Schedule II, the incremental effort to extend it to Schedule III–V is modest. The accountability benefit is significant.

Enforce dual verification consistently. This is a policy and culture issue, not a resource issue. If your dual verification policy is inconsistently applied, the fix is leadership commitment and workflow design — not additional staff.

Implement shift-end reconciliation. Building a 10–15 minute reconciliation into the end-of-shift routine creates accountability boundaries that make discrepancies traceable.

Standardize DEA documentation. Create a written protocol for every DEA documentation requirement your pharmacy faces. Train staff on the protocol. Audit compliance regularly.

Review controlled substance data proactively. Designate a weekly review of controlled substance transaction data. You don't need sophisticated analytics software — a structured review of your existing reports will surface patterns that warrant investigation.

Controlled substance diversion in healthcare is more common than the industry likes to admit. The DEA estimates that diversion affects thousands of healthcare facilities annually, and the majority of cases involve pharmacy staff rather than external theft.

The consequences — for patients who receive diluted medications, for staff members whose careers are destroyed, for institutions facing DEA sanctions and reputational damage — are severe.

VAMC pharmacies have built accountability systems that reflect the seriousness of those stakes. Community hospitals that adopt similar practices aren't just reducing compliance risk. They're protecting their patients, their staff, and their institutions.

The standard VAMC pharmacies operate to isn't unreachable. It's a choice about how seriously to take controlled substance accountability — and what operational practices that commitment requires.

At IMC Pharma, we work with hospital pharmacies to build exactly these kinds of accountability systems. If your controlled substance processes could benefit from a structured review, I'd welcome the conversation.